Press Releases

    • APR 07 2020

    Co-Founder and CEO Wolfgang Oster Departs from Oncoceutics

    Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of compounds called imipridones, announced today that Wolfgang Oster, MD, PhD, one of the company’s co-founders and Chief Executive Officer, has left the company effective April 3 as part of a leadership change.  He has also

    • APR 01 2020

    Phase I/II Clinical Study of ONC201 Begins in Japan

    Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co., Ltd., of the initiation of a Phase I/II clinical study of OP-10 (the Japanese name for ONC201) in Japan and the administration of the drug to the first patient.  ONC201 is a novel small molecule